Primary esophageal epithelial cells (keratinocytes) from normal human esophagus were established as described previously. 6 Fetal esophageal fibroblasts (FEF) were isolated as previously described ...

Learn more about the high-purity GMP-grade human activin A / INHBA protein, designed for therapeutic and research ...

在市场强劲势头推动下，iBio Inc.股价飙升至52周新高，触及5.03美元。对于这家专注于开发和生产植物制药的生物技术公司来说，这一价格水平代表着重要里程碑。根据 InvestingPro 数据显示，该股票的贝塔系数为-3.29，往往与市场趋势相反。过去一年，iBio股价实现了221.37%的显著回报，尤其在过去六个月中表现强劲，涨幅达95.83%。虽然收入增长达650%， ...

PASADENA, CA, USA I February 25, 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s ...

(NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed ...

Takeda has agreed to receive an exclusive global licence from Keros Therapeutics to advance the development, manufacture and commercialisation of the investigational activin inhibitor elritercept ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress.